$0.02
0.00%
Nasdaq, Nov 22, 03:30 pm CET
ISIN
US43358Y1038
Symbol
HSTO
Sector
Industry

Histogen Inc Stock price

$0.02
-0.28 93.33% 1M
-0.15 88.24% 6M
-0.29 93.50% YTD
-0.32 94.03% 1Y
-10.50 99.81% 3Y
-68.61 99.97% 5Y
-1,601.98 100.00% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.00 0.00%
ISIN
US43358Y1038
Symbol
HSTO
Sector
Industry

Key metrics

Market capitalization $90.00k
Enterprise Value $-5.81m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.58
EV/Sales (TTM) EV/Sales -290.50
P/S ratio (TTM) P/S ratio 4.50
P/B ratio (TTM) P/B ratio 0.02
Revenue growth (TTM) Revenue growth -99.50%
Revenue (TTM) Revenue $20.00k
EBIT (operating result TTM) EBIT $-12.08m
Free Cash Flow (TTM) Free Cash Flow $-10.08m
Cash position $4.87m
EPS (TTM) EPS $-2.90
Short interest 1.62%
Show more

Is Histogen Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Histogen Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Histogen Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Histogen Inc:

Buy
100%

Financial data from Histogen Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '23
+/-
%
0.02 0.02
99% 99%
100%
- Direct Costs 0.18 0.18
157% 157%
900%
-0.16 -0.16
104% 104%
-800%
- Selling and Administrative Expenses 8.47 8.47
6% 6%
42,350%
- Research and Development Expense 3.28 3.28
41% 41%
16,400%
-12 -12
-
-59,550%
- Depreciation and Amortization 0.18 0.18
-
900%
EBIT (Operating Income) EBIT -12 -12
12% 12%
-60,420%
Net Profit -12 -12
15% 15%
-61,900%

In millions USD.

Don't miss a Thing! We will send you all news about Histogen Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Histogen, Inc., a regenerative medicine company, develops therapies based upon the products of cells grown under simulated embryonic conditions. The company engages in research, development, and manufacturing of products derived from its technology. It offers an insoluble human extracellular matrix (hECM); and a soluble complex of proteins. The company's technology focuses on stimulating a patient's own stem cells by delivering a complex of multipotent human proteins that support stem cell growth and differentiation. It has joint venture with PUR Biologics, Adaptive Biologix, and Histogen Aesthetics to develop additional products. Histogen, Inc. was founded in 2007 and is based in San Diego, California.

Head office United States
CEO Susan Knudson
Founded 2005
Website www.histogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today